Metabolomic Signatures for Drug Response Phenotypes

Pharmacometabolomics Enables Precision Medicine

Pharmacometabolomics Research Network

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The scaling up of data in clinical pharmacology and the merger of systems biology and pharmacology has led to the emergence of a new discipline of Quantitative and Systems Pharmacology (QSP). This new research direction might significantly advance the discovery, development, and clinical use of therapeutic drugs. Research communities from computational biology, systems biology, and biological engineering--working collaboratively with pharmacologists, geneticists, biochemists, and analytical chemists--are creating and modeling large data on drug effects that is transforming our understanding of how these drugs work at a network level. In this review, we highlight developments in a new and rapidly growing field--pharmacometabolomics--in which large biochemical data-capturing effects of genome, gut microbiome, and environment exposures is revealing information about metabotypes and treatment outcomes, and creating metabolic signatures as new potential biomarkers. Pharmacometabolomics informs and complements pharmacogenomics and together they provide building blocks for QSP.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume98
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Precision Medicine
Metabolomics
Systems Biology
Pharmacology
Phenotype
Pharmaceutical Preparations
Bioengineering
Clinical Pharmacology
Pharmacogenetics
Therapeutic Uses
Computational Biology
Research
Biomarkers
Genome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Metabolomic Signatures for Drug Response Phenotypes : Pharmacometabolomics Enables Precision Medicine. / Pharmacometabolomics Research Network.

In: Clinical Pharmacology and Therapeutics, Vol. 98, No. 1, 01.07.2015, p. 71-75.

Research output: Contribution to journalArticle

@article{fb06218051614186b2270d1949fa3857,
title = "Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine",
abstract = "The scaling up of data in clinical pharmacology and the merger of systems biology and pharmacology has led to the emergence of a new discipline of Quantitative and Systems Pharmacology (QSP). This new research direction might significantly advance the discovery, development, and clinical use of therapeutic drugs. Research communities from computational biology, systems biology, and biological engineering--working collaboratively with pharmacologists, geneticists, biochemists, and analytical chemists--are creating and modeling large data on drug effects that is transforming our understanding of how these drugs work at a network level. In this review, we highlight developments in a new and rapidly growing field--pharmacometabolomics--in which large biochemical data-capturing effects of genome, gut microbiome, and environment exposures is revealing information about metabotypes and treatment outcomes, and creating metabolic signatures as new potential biomarkers. Pharmacometabolomics informs and complements pharmacogenomics and together they provide building blocks for QSP.",
author = "{Pharmacometabolomics Research Network} and R. Kaddurah-Daouk and Weinshilboum, {Richard M}",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/cpt.134",
language = "English (US)",
volume = "98",
pages = "71--75",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Metabolomic Signatures for Drug Response Phenotypes

T2 - Pharmacometabolomics Enables Precision Medicine

AU - Pharmacometabolomics Research Network

AU - Kaddurah-Daouk, R.

AU - Weinshilboum, Richard M

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The scaling up of data in clinical pharmacology and the merger of systems biology and pharmacology has led to the emergence of a new discipline of Quantitative and Systems Pharmacology (QSP). This new research direction might significantly advance the discovery, development, and clinical use of therapeutic drugs. Research communities from computational biology, systems biology, and biological engineering--working collaboratively with pharmacologists, geneticists, biochemists, and analytical chemists--are creating and modeling large data on drug effects that is transforming our understanding of how these drugs work at a network level. In this review, we highlight developments in a new and rapidly growing field--pharmacometabolomics--in which large biochemical data-capturing effects of genome, gut microbiome, and environment exposures is revealing information about metabotypes and treatment outcomes, and creating metabolic signatures as new potential biomarkers. Pharmacometabolomics informs and complements pharmacogenomics and together they provide building blocks for QSP.

AB - The scaling up of data in clinical pharmacology and the merger of systems biology and pharmacology has led to the emergence of a new discipline of Quantitative and Systems Pharmacology (QSP). This new research direction might significantly advance the discovery, development, and clinical use of therapeutic drugs. Research communities from computational biology, systems biology, and biological engineering--working collaboratively with pharmacologists, geneticists, biochemists, and analytical chemists--are creating and modeling large data on drug effects that is transforming our understanding of how these drugs work at a network level. In this review, we highlight developments in a new and rapidly growing field--pharmacometabolomics--in which large biochemical data-capturing effects of genome, gut microbiome, and environment exposures is revealing information about metabotypes and treatment outcomes, and creating metabolic signatures as new potential biomarkers. Pharmacometabolomics informs and complements pharmacogenomics and together they provide building blocks for QSP.

UR - http://www.scopus.com/inward/record.url?scp=84940545374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940545374&partnerID=8YFLogxK

U2 - 10.1002/cpt.134

DO - 10.1002/cpt.134

M3 - Article

VL - 98

SP - 71

EP - 75

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -